Antibiotic Resistance and New UTI Treatments: What Payers Need to See
Urinary tract infections (UTIs) rank as the most common bacterial infection for women worldwide. Between 50-60% of adult women experience at least one UTI in their lifetime, and approximately 25% of them suffer recurring infections, defined as two or more episodes within six months. As the prevalence of recurring infection increases with age, older women […]
Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification
This article was originally published in Drug Channels. As patient access grows more complex, manufacturers need tools that reduce friction throughout the care journey. One valuable but frequently overlooked dataset is known as BIN/PCN/Group (BPG) data, which refers to a trio of identifiers used in pharmacy claims processing. Unlocking the power of BPG data can […]
New Treatments, Diagnostic Tests and Access Barriers in NSCLC
The oncology market is growing rapidly, driven by advancements in diagnostic technology, new biomarker testing, and a wealth of targeted therapies. The non-small cell lung cancer (NSCLC) space is especially crowded, which should be good news for the 226,000 patients diagnosed with this disease each year. Despite the new developments in NSCLC treatment, however, many […]
A New Era in HAE: How Market Entrants Are Reshaping Rare Disease Treatment
As medicine evolves, even smaller therapeutic areas are impacted by scientific breakthroughs and novel technologies, leading to an eruption of new therapies. Hereditary angioedema (HAE), a rare genetic disorder affecting 1 in 50,000 people worldwide, is the latest indication to reap the benefits of several new market entrants. Due to a deficiency of the C1 […]
How to Mitigate Payer Pushback on Fast-Tracked Therapies
For pharma manufacturers, securing expedited approval for a drug in development is typically seen as a win, which will result in faster patient access as well as faster revenue recognition. However, the realities of market access mean that drugs approved by expedited pathways—most notably, the accelerated approval pathway—may face a much more difficult path to […]
Drive HCP Engagement with Smarter Omnichannel Marketing
Pharma companies have made significant strides in omnichannel marketing, building programs that engage healthcare professionals (HCPs) across email, digital, social, and peer-to-peer platforms. However, many of these campaigns are often based on static HCP lists and pre-scheduled sequencing, leaving brand teams unable to adapt to clinical events as they occur. Real-world data (RWD) changes that […]
Impact of the New Administration on Vaccine Policy and Access
Manufacturers should be prepared for a period of uncertainty and potential disruption in vaccine policy. The recent overhaul of the CDC’s Advisory Committee on Immunization Practices (ACIP) signals a shift that could affect vaccine recommendations, public trust, and payer coverage decisions. After Robert F. Kennedy Jr. was sworn in as the new secretary of the […]
The Rise in Biotech Commercialization
In 2024, biotechs were behind almost two-thirds of the FDA’s new drug approvals. Many biotechs are choosing to commercialize their products themselves, rather than partnering with Big Pharma players. Many fail, but some market factors are now in biotech’s favor. A recent Evaluate report, Going Solo: Commercializing Biotech, analyzes the dynamics that are enabling biotech […]
Contextualizing Market Access: How Advisors Bridge the Knowledge Gap
For pharma companies, securing favorable coverage for a new asset is far more complicated than it used to be. Indications are more competitive, and the market is full of specialized niche therapies for smaller patient populations. While market access data has never been easy to parse, we’ve seen an evolution in the amount and type […]
Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization
This article was originally published in Drug Channels. To chart a clear path to commercialization, a manufacturer must begin with the end in mind. Early market research helps pharma companies understand which clinical endpoints and differentiators an asset will need to succeed at launch. Today, one-third of pharma companies start market access planning in Phase I, and […]